Sentynl Therapeutics Clinches Award with Acquisition of Zokinvy
Deal News | Feb 19, 2025 | Pillsbury Winthrop Shaw Pittman LLP
Sentynl Therapeutics, a U.S.-based biopharmaceutical company, has been awarded the 2025 'Distressed M&A Deal of the Year' at the 16th Annual Americas M&A Atlas Awards Gala in New York City for its acquisition of the Zokinvy program from Eiger Biopharmaceuticals. This acquisition was accomplished through a chapter 11 sale process where Sentynl emerged as the winner in a competitive auction, serving as the stalking horse bidder. With this acquisition, Sentynl has obtained global rights to Zokinvy, the first FDA-approved treatment for progeria, and taken on responsibilities for its manufacturing and commercialization. Pillsbury Winthrop Shaw Pittman LLP advised Sentynl in this transaction, with a deal team led by Corporate partner Jason Stirling and Insolvency & Restructuring partner Joshua Morse.
Sectors
- Biopharmaceuticals
- Legal Services
- Mergers and Acquisitions
Geography
- United States – Sentynl Therapeutics is a U.S.-based company, and the acquisition involves global rights to a U.S. FDA-approved treatment.
- North America – The article references the Americas M&A Atlas Awards, highlighting the North American transaction and corporate environment.
Industry
- Biopharmaceuticals – The article discusses Sentynl Therapeutics, a biopharmaceutical company, and its acquisition of the Zokinvy program, a treatment for an extremely rare disease.
- Legal Services – Pillsbury Winthrop Shaw Pittman LLP, a law firm, advised Sentynl in the acquisition deal, showcasing the firm's involvement in legal advisory services for M&A.
- Mergers and Acquisitions – The article covers the acquisition of Zokinvy by Sentynl Therapeutics, categorized as a distressed M&A deal.
Financials
- Not disclosed – The financial terms of Sentynl Therapeutics' acquisition of Zokinvy were not mentioned in the article.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Sentynl Therapeutics, Inc. | Acquirer | Company | A U.S.-based biopharmaceutical company that acquired the Zokinvy program. |
| Eiger Biopharmaceuticals | Seller | Company | The company from which Sentynl acquired the Zokinvy program. |
| Pillsbury Winthrop Shaw Pittman LLP | Legal Advisor | Company | The law firm that advised Sentynl Therapeutics in the acquisition deal. |
| Jason Stirling | Corporate Partner | Person | Led the Pillsbury deal team advising on the transaction. |
| Joshua Morse | Insolvency & Restructuring Partner | Person | Involved in advising on the acquisition deal as part of the Pillsbury team. |